China Approves GSK's Nucala as Add-on Treatment for Chronic Obstructive Pulmonary Disease

02:31 AM EST, 01/05/2026 (MT Newswires) -- GSK (GSK.L) said Monday it secured approval from China's National Medical Products Administration for Nucala, or mepolizumab, as an add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease. The approval is specific for the monthly use of the medication on adults exhibiting the disease through raised blood eosinophils. The pharmaceutical company said the approval was based on positive results of the Matinee and Metrex phase 3 trials.